Market's view on Ovoca Bio
Published on April 2024
- A Stock watcher mentioned a failed drug study where a placebo spray might be repurposed as a ‘clinically proven’ medical device, hinting at possible regulatory approval and market opportunities similar to another company’s strategy.
- There are discussions around the disappointing results from the Australian and New Zealand Orenetide trial, with explanations that clinical trials inherently possess risks and uncertain outcomes.
- Questions were raised about the oversight of previous Russian Orenetide trials which were managed by a reputable Russian CRO, and the future of Orenetide remains uncertain as further assessments are ongoing.
- Concerns were raised about the company’s silence and lack of updates, with some watchers questioning the continuation of the Orenetide project and suggesting the company might turn into an attractive cash shell.
- There is discussion about the company’s market valuation being substantially below its cash levels, raising issues about its financial strategy and asset management.
- Some Stock watchers are optimistic about the company’s potential despite setbacks, suggesting that the current low stock price presents a good buying opportunity.
- A few express frustrations over the lack of communication from the company regarding updates or strategic directions, particularly around the AGM and its aftermath.
- One Stock watcher criticizes the management’s handling of the situation, implying a lack of transparency and questioning the validity of initial trial data.